ReviewAsian Pacific journal of cancer prevention : APJCP2025
Bringing DARC to Light: Role of Duffy Antigen/Receptor in Breast Cancer Progression and Cancer Prevention.
Review in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuffy Antigen/Receptor for Chemokine (DARC), also called Atypical Chemokine Receptor 1 (ACKR1), is a seven-transmembrane receptor expressed on erythrocytes, lymphatic and vascular endothelial cells, keratinocytes, neurons, etc. ACKR1 is incapable of traditional G protein-coupling signaling and instead functions as a "decoy receptor," binding multiple chemokines and facilitating their internalization and degradation. This regulates immune responses and inflammation, making it significant in the context of breast cancer.
methodsA comprehensive literature search was performed using keywords including "Duffy Antigen/Receptor for Chemokine (DARC)", "Atypical Chemokine Receptor 1 (ACKR1)", and "breast cancer". Studies assessing ACKR1 expression in various breast cancer subtypes and its correlation with patient outcomes were analyzed.
resultsReduction in the levels of pro-angiogenic chemokines such as CCL2 can inhibit tumor growth, angiogenesis, and metastasis. High expression of ACKR1 is related to improved patient outcomes, such as enhanced disease-free survival. Conversely, low ACKR1 expression is associated with increased metastatic risk, especially in aggressive subtypes like triple-negative breast cancer.
conclusionsGiven its potential as a biomarker and therapeutic target, further investigation into DARC's mechanisms may reveal new strategies for cancer prevention and treatment. Overall, ACKR1 is a promising area of research, providing information about the interplay between inflammation, tumor progression, and immune surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.